Genuv Inc., a clinical-stage biotechnology startup focused on drug discovery, and South Korea headquartred Celltrion, a leading global biopharmaceutical company, have entered into a partnership to jointly discover and develop novel therapeutic antibodies using Genuv's proprietary SHINE MOUSE platform.

Under the terms of agreement, Genuv will conduct antibody discovery service using the SHINE MOUSE technology to be followed by research collaboration. If Celltrion exercises its option for joint research and development projects, the agreed milestones are: development milestones up to $25 million followed by total commercial milestones up to $680 million in case of accumulated $7.5 billion sales of per candidate antibody.

The SHINE MOUSE platform generates antibodies with greater diversity compared to conventional mice, which led to the discovery of the experimental, novel anti-PD-1 monoclonal antibody (mAb), GNUV201.

GNUV201 has the unique feature of exceptional interspecies cross-reactivity and binding affinity allowing preclinical disease animal model studies with increased clinical relevance. Additionally, Genuv is developing GNUV205, an improved IL-2-based immunocytokine anticancer drug that is made tumor-specific by leveraging the properties of GNUV201. Genuv currently has NuvoFc platform, which enables the design and discovery of new bi-/multi-specifics. Furthermore, the NuvoMab platform, which directly discovers human antibodies, is nearing completion of development.